Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Obesity Treatments

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

The company says it will review physician requests under narrow medical criteria to supply a small number of patients with the drug before a planned FDA filing.

35 ARTICLES

last mo.

One 79-Year-Old Granted Compassionate‑Use Access to Eli Lilly’s Unapproved Obesity Drug

16 ARTICLES

2mo ago

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

11 ARTICLES

2mo ago

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

45 ARTICLES

2mo ago

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

12 ARTICLES

2mo ago

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

35 ARTICLES

2mo ago

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

6 ARTICLES

3mo ago

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

3 ARTICLES

5mo ago

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

33 ARTICLES

5mo ago

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

41 ARTICLES

6mo ago

Novo Nordisk Sues Hims & Hers to Halt Compounded Wegovy Copycats

46 ARTICLES

6mo ago

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

3 ARTICLES

6mo ago

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

9 ARTICLES

6mo ago

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

9 ARTICLES

6mo ago

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

4 ARTICLES

7mo ago

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

14 ARTICLES

8mo ago

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

5 ARTICLES

9mo ago

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

45 ARTICLES

9mo ago

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

38 ARTICLES

11mo ago

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Obesity Treatments

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

One 79-Year-Old Granted Compassionate‑Use Access to Eli Lilly’s Unapproved Obesity Drug

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Never miss stories about

Obesity Treatments

Novo Nordisk Sues Hims & Hers to Halt Compounded Wegovy Copycats

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Never miss stories about

Obesity Treatments